Expanded Access to OKN-007 for Patients With Diffuse Midline Glioma, H3 K27-altered

NCT05518838 · clinicaltrials.gov ↗

NO_LONGER_AVAILABLE

Status

INDUSTRY

Sponsor class

Conditions

Diffuse Midline Glioma, H3 K27M-Mutant
Diffuse Intrinsic Pontine Glioma

Interventions

DRUG: OKN-007

Sponsor

Oblato, Inc.